News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bringing next-gen cannabinoid therapeutics to cancer patients
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Many kids who have heart transplants live a normal, healthy life once they recover from surgery.
63-year old woman gets rare Transcatheter Tricuspid Valve Replacement (TTVR)
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
